KASBP
SAN FRANCISCO

KASBP-SF SYMPOSIUM 2024

Scientific exchange, collaboration, and networking opportunities among professionals in biotech, pharma, academia, and government



JANUARY 6, 2024

Embassy Suites by Hilton San Francisco Airport
(250 Gateway Blvd, South San Francisco, CA 94080)

SYMPOSIUM SCHEDULE

8:30-9:30 Registration with light breakfast

Opening and Congratulatory Remarks — Facilitator: OhKyu Yoon

9:00-9:05 President, KASBP-SF — OhKyu Yoon

9:05-9:10 President, KASBP — Ik-Hyeon Paik

Session 1

Advanced Analytics for Drug Discovery and Development — Chair: Meena Choi

9:10-9:40 Meta-Analysis to Data Fusion — Mi-Ok Kim, UCSF

9:40-10:10 Bridging timescales between simulations and biological processes for computer-aided drug discovery — Surl-Hee Ahn, UC-Davis

10:10-10:40 A Tale of Many Tails: Multi-Objective Bayesian Optimization for Molecular Design — Ji Won Park, Genentech

10:40-10:55 Coffee Break

Sponsor Presentation I

Moderator: Soojin Kim

10:55-11:10 KEIT – Sunghwan Park

11:10-11:25 Yuhan USA – Taewon Yoon

11:25-11:35 Dong-A ST – Yehwang Cheong

11:35-11:50 Samyang Holdings – Sean Kim

Instructions for Networking and Group Photo — Announcer: Sang Kim

11:50-12:10 Group Photo — Photographer: Siyeon Rhee

12:10-1:05 Lunch

1:05-2:20 Networking — Moderator: Karam Kim

Session 2

Innovative platform and start-ups — Chair: Jin-Hwan Han

2:20-2:50 Microengineered biomimicry of human physiological systems — Dan Huh, Upenn / Vivodyne

2:50-3:20 Bifunctional protein degraders :basic discovery to drug development — HwaJin Lee, Kyunhee Univ. / Uppthera

3:20-3:50 Neurodegenerative disease therapeutics development — Jae Moon Lee, Fascinate Therapeutics

3:50-4:05 Coffee Break

Sponsor Presentation II

Moderator: Agatha Lee

4:05-4:20 LegoChemBio Inc. – Jeiwook Chae

4:20-4:35 GI Innovation – Nari Yun

4:35-4:45 Hanmi Pharmaceutical – Jae Yun Lee

4:45-4:55 GC Cell – James Park

4:55-5:00 Closing Remarks - KASBP-SF President — OhKyu Yoon

Session 1

SPEAKERS

Mi-Ok Kim, Ph.D.

- Professor, Division Head of Biostatistics, and Vice Chair of Finance
  Department of Epidemiology and Biostatistics
  University of California, San Francisco
- Director of Biostatistics and Population Research Shared Resources
  Helen Diller Family Comprehensive Cancer Center

Dr. Mi-Ok Kim is the Director of the Biostatistics Core at UCSF Helen Diller Family Comprehensive Cancer Center, responsible for providing support for protocol development, review and analysis for clinical studies, and statistical expertise for research collaborations with Cancer Center investigators in all disciplines across the spectrum of basic, clinical and population sciences.

Dr. Kim is also a Professor of Biostatistics in the Department of Epidemiology of UCSF, continuing academic contributions to the field of biostatistics and providing biostatistical support broadly on campus. Trained as a mathematical statistician, Dr. Kim is an independent statistical method researcher with research interest in non- and semi-parametric statistics and longitudinal and survival data analysis. Her recent research focuses on causal inference using structured data for comparative effectiveness research (CER) and patient-centered outcome research (PCOR).

Dr. Kim joined UCSF from Cincinnati Children's Hospital Medical Center in Cincinnati, OH, where she directed the Biostatistics Unit for the Cancer and Blood Diseases Institute. Notable collaborations included Children's Tumor Foundation's Neurofibromatosis (NF) Therapeutic Consortium which builds up a preclinical pipeline for screening candidate drug therapies in animal model systems. Dr. Kim also developed a research program in novel clinical trial designs that incorporate biomarker information and aim to optimize patient benefits.

Abstract

Meta-Analysis to Data Fusion

The advances of information technologies often confront users with a large amount of data. The field of data fusion also known as statistical matching aims to integrate the overall information from multiple data sources for a better understanding of the phenomena that interact in the population. This presentation will provide an overview of information synthesizing techniques starting with conventional meta-analysis to more recent data fusion techniques.

Surl-Hee (Shirley) Ahn, Ph.D.

- Assistant Professor
  Department of Chemical Engineering
  University of California, Davis

Dr. Surl-Hee (Shirley) Ahn is an Assistant Professor in the Department of Chemical Engineering at the University of California Davis. She received her B.A. in Biochemistry and Mathematics, M.A. in Mathematics, and M.S. in Chemistry at the University of Pennsylvania, and her Ph.D. in Chemistry (Chemical Physics) at Stanford University, advised under Prof. Eric Darve. Subsequently, she worked as a postdoctoral scholar in the Department of Chemistry and Biochemistry at the University of California, San Diego (UCSD), advised under Prof. J. Andrew McCammon and Prof. Rommie Amaro, before starting her independent career at the University of California, Davis. Surl-Hee is interested in developing enhanced sampling methods for molecular dynamics simulations and applying those methods to study important biophysical phenomena. She was selected to participate in the 2018 MIT Rising Stars in Mechanical Engineering Workshop, was awarded the 2021 ACS PHYS Division Young Investigator Award, and was a finalist for the 2021 Chancellor's Outstanding Postdoctoral Scholar Award at UCSD.

Abstract

Bridging timescales between simulations and biological processes for computer-aided drug discovery

To investigate the structures and dynamics of biological processes at an atomic level, molecular dynamics (MD) simulations can be useful since they can effectively serve as a computational microscope. However, MD simulations are run using femtosecond time steps due to being limited by the fastest motions in the system, and they cannot reach biologically relevant timescales on the order of milliseconds or longer in a computationally tractable period. Thus, we have been developing enhanced sampling methods for MD simulations to bridge the timescales and make MD simulations closer to being a true computational microscope that uncovers the fundamental mechanisms of biological processes. In this talk, I will present and discuss both efforts.

Session 1
SPEAKERS

Ji Won Park, Ph.D.

- Senior Machine Learning Scientist
  Prescient Design Team
  Genentech

Dr. Ji Won Park is a Senior Machine Learning Scientist in the Prescient Design team at Genentech. Her current research probes hierarchical, sparsity-inducing structures in high-dimensional data that can inform optimization, inference, and adaptive decision-making. She focuses on developing algorithms in Bayesian optimization, MCMC sampling, and causal representation learning inspired by challenges in molecular design.

In her past life as an astrophysicist, she studied gravitational lensing using hierarchical Bayesian models to understand the origin and evolution of the Universe. She interned at NASA Ames and the Center for Computational Astrophysics at the Flatiron Institute while pursuing her Ph.D. in Physics at Stanford University, which she completed in 2022 under the supervision of Phil Marshall and Aaron Roodman. She holds B.S. degrees in Mathematics and Physics from Duke University (2017).

Abstract

A Tale of Many Tails: Multi-Objective Bayesian Optimization for Molecular Design

Active design of therapeutic molecules requires the joint optimization of multiple, potentially competing properties. Multi-objective Bayesian optimization (MOBO) offers a sample-efficient framework for identifying Pareto-optimal drug candidates. MOBO proceeds in cycles, a single iteration of which involves (1) sampling molecules from a combinatorially vast design space, (2) inferring multiple properties of interest, and (3) selecting the most promising subset for wet-lab evaluation. In this talk, I highlight the importance of modeling the tails – extreme, low-probability events – in biological applications and propose algorithms designed to accommodate complex tail behavior in each of these steps. Together, the algorithms enable modeling flexibility beyond that afforded by the common log-concave (e.g., Gaussian) assumption.

Session 2
SPEAKERS

Dongeun (Dan) Huh, Ph.D.

- Associate Professor
  Department of Bioengineering
  University of Pennsylvania
- Chief Scientific Officer and Co-Founder
  Vivodyne

Dr. Dan Huh is an Associate Professor in the Department of Bioengineering at the University of Pennsylvania. He is a pioneer of organ-on-a-chip technology, and his research group at Penn focuses on developing microengineered models of human physiological systems for biomedical and environmental applications. Dr. Huh has won several honors and awards including the PCI Inventor of the Year Award, the Bernard Langer Distinguished Lectureship, Lush Prize, the McPherson Distinguished Lectureship, CRI Technology Impact Award, John J. Ryan Medal, the Design of the Year Award and Best Product of the Year Award from London Design Museum, NIH Director's New Innovator Award, Analytical Chemistry Young Innovator Award, TEDx Fellow, NC3Rs Annual Award, Lifetime Membership from MOMA, SLAS Innovation Award from the Society for Lab Automation and Screening, Scientific Breakthrough of the Year Award from American Thoracic Society, Best Publication Award from the Society of Toxicology, Wyss Technology Development Fellowship from Harvard, and Distinguished Achievement Award from Michigan.

Abstract

Microengineered biomimicry of human physiological systems

Remarkable progress in life science and technology in the past century has advanced our understanding of the human body beyond our imagination. The ever-increasing knowledge of human biology, however, has done surprisingly little to change and improve the way we emulate the complex inner workings of human health and disease in experimental models. Even today, our ability to mimic and study the key aspects of human physiological systems relies on the century-old practice of cell culture or animal experimentation which often raises significant scientific and ethical concerns. This lack of realistic and human-relevant model systems with high predictive capacity is emerging as a critical impediment to our scientific endeavors for a wide variety of biomedical applications. Motivated by this major problem, this talk will present interdisciplinary research efforts in my laboratory to develop advanced in vitro models and preclinical research platforms that leverage the power of microengineering technologies to emulate the complexity of human tissues and functional elements of human organs for biomedical and environmental applications.

Session 2

SPEAKERS

HwaJin Lee, Ph.D.

- Assistant Professor in Biochemistry and Molecular Biology
  Kyung Hee University School of Medicine
- Chief Development Officer and Co-Founder
  UPPThera

Dr. HwaJin Lee is an Assistant Professor at Kyunghee University School of Medicine. He is also a Co-founder of UPPThera, Inc., a biotechnology company located in the Republic of Korea, where he currently serves as a Chief Development Officer overseeing the development pipeline of drugs and platforms. He served as an adjunct principal investigator at Seoul National University School of Dentistry. Before joining as a faculty, he spent 5 years at a Korea-based global biopharmaceutical company, Celltrion, Inc., pioneering new drug development along with planning and coordinating drug products. He graduated from Johns Hopkins School of Medicine with a PhD in Cellular and Molecular Medicine. He holds a BS in Biological Sciences from Cornell University.

Abstract

Bifunctional protein degraders: basic discovery to drug development

Drug modalities utilizing targeted protein degradation (TPD) have massively evolved in recent days, which not only boosted academic research aiming to study protein functions but also gave rise to multiple protein-degrading drugs in the clinic. Starting from early generation FDA-approved protein degrading compounds like IMiDs (ex. lenalidomide (REVLIMID®)) and SERDs (ex. fulvestrant (Faslodex)), numerous compounds with different modalities (molecular glues, SERDs, bifunctional degraders, Degrader-Antibody conjugates (TPD2), etc.) are in the clinical stages. Of these new generation TPD drugs, bifunctional degraders (a.k.a proteolysis targeting chimera (PROTACs), BiDACs, etc.) induce ternary complex (target protein / bifunctional degrader molecule / E3 ligase), thus polyubiquitinating the target protein followed by the ubiquitin-proteasome system (UPS)-mediated protein degradation. In this talk, I will introduce the rationale (potential competitive advantages to the conventional targeted therapy inhibitors), mechanisms of action, and key results regarding our lead pipeline, PLK1 bifunctional degrader.

Jae Moon Lee, Ph.D.

- President and Board
  FAScinate Therapeutics
- President and Board
  Kainos Medicine

Dr. Jae Moon Lee is the President of FAScinate Therapeutics located in San Diego, California. He is also the President of Kainos Medicine, Korean biotech and the parent company of FAScinate. Currently, he is leading the clinical development of KM-819 for Parkinson's Disease (PD) and Multiple System Atrophy (MSA), both neurodegenerative diseases and synucleinopathies. Before joining Kainos Medicine, he spent 14 years in three biotech companies in the Bay Area including EXELIXIS Pharmaceuticals. In EXELEXIS, he was involved in many oncology programs, mostly targeting protein kinases. He graduated from Duke University with a Ph.D. in Biochemistry and postdoctoral training. Also at Duke, he was a research assistant professor in Dr. Robert Lefkowitz's la-laboratory who received a Nobel Prize in 2012. At the time, he conducted research on GPCRs such as adrenergic receptors and dopamine receptors. In Kora, he graduated from Sogang University with a BS in Biology and KAIST with an MS in Biochemistry.

Abstract

Neurodegenerative disease therapeutics development

Parkinson's Disease or PD is a neurodegenerative disease caused by the progressive death of dopaminergic neuron cells in the Substantia nigra in the midbrain, the resulting shortage of dopamine neurotransmitters, and a deficit of movement control. It is detrimental affecting human life and progressing to death in 15-20 years. It is the second most common CNS disease, in particular, elderly people, next to Alzheimer's. Currently, there are many drugs treating the disease but all are symptomatic therapies such as dopamine precursors, metabolism inhibitors, and receptor agonists, but these drugs cannot cure or stop the progression. We are targeting the disease by inhibiting the apoptosis pathway by inhibiting the proapoptotic protein FAF1 to develop the disease-modifying drug, halting or slowing down the progression. Our development drug is currently in the clinical trial phase 2 for proof of concept (POC), PD in the US, and MSA in Korea.

SPONSORS

GOLD

LegoChemBio

YUHAN

GI Innovation

KEIT 한국산업기술기획평가원 Korea Planning & Evaluation Institute of Industrial Technology

SILVER

주샌프란시스코 대한민국 총영사관 Consulate General of the Republic of Korea in San Francisco

Hanmi Global · R&D Leader Hanmi Pharm.

ablbio medicine for a better life

CUROCELL

GC Cell

DONG-A ST

samyang

BRONZE

UPPTHERA

ONEGENE BIOTECHNOLOGY

(주)카나프테라퓨틱스 Kanaph Therapeutics Inc.

COMMITTEE

President	윤오규 Oh Kyu Yoon	Gilead Sciences
President Team	김상엽 Sang Yeop Kim	Merck
Finance Team	조향 Hyang Cho	Genentech
	이동은 Agatha Lee	Batavia Biosciences
Science Team	한진환 Jin-Hwan Han	Merck
	김가람 Karam Kim	Genentech
	조효석 Hyosuk Cho	Sangamo Therapeutics
PR·Membership Team	최미나 Meena Choi	Genentech
	박준희 Joonhee Park	Amgen
	황승용 Seung Yong Hwang	GRAIL
	장아람 Aram Chang	Bristol Myers Squibb
	이현철 Hyuncheol Lee	Stealth mode startup
	김수진 Soojin Kim	Genentech
	김기철 Kicheol Kim	Everest Detection
Councilor	임한조 Hanjo Lim	Genentech
	마성훈 Sunghoon Ma	Exelixis
	정준원 Joon Won Jeong	Exelixis
	정가영 Claire Jeong	Genentech

Sign up for KASBP·SF membership on our website

www.kasbpsf.org

KASBP·SF membership is free.

Receive announcements on upcoming events

KASBP SAN FRANCISCO

KASBP-SF Symposium 2024 Attendees

Early Bird registrants only

	Name	이름	Company/Institution	Networking Group
1	**Surl-Hee Ahn**	안설희	University of California, Davis	1
2	**Kazuko Aoyagi**		Celerion Inc	2
3	**Kern Chang**	장건희	Lotte Biologics USA LLC	6
4	**Chong Hwan Chang**	장종환	Beyond Pacific Bio	6
5	**Han Chang**	장한	Scribe Therapeutics	1
6	**Yong Cho**	조용성	YC Consulting	3
7	**Wansang Cho**	조완상	Stanford	1
8	**Iltaeg Cho**	조일택	Bristol Myers Squibb	5
9	**Hyosuk Cho**	조효석	Sangamo Therapeutics	5
10	**Meena Choi**	최미나	Genentech	4
11	**Younjeong (YJ) Choi**	최연정	Genentech	4
12	**Yongbin Choi**	최용빈	Simon-Kucher	6
13	**Wooil Choi**	최우일	UCSD	1
14	**Angie Jiwon Chun**	전지원	GC Cell	6
15	**Kyung Chun**	전경우	U.S. Department of Veterants Affairs	1
16	**Yunsie Chung**	정윤지	Merck	4
17	**Alex Chung**	정관호	Perkins Coie LLP	6
18	**Cheol Chung**	정철근	Merck	3
19	**Seung Wook Chung**	정승욱	Johnson & Johnson	2
20	**Jung Ethan**	정인영	Synthekine	1
21	**Jin-Hwan Han**	한진환	Merck & Co	1
22	**Su Hong**	홍수현	TrueBinding	3
23	**Nan Hyung Hong**	홍난형	ESSA Pharma	1
24	**Dan Huh**	허동은	University of Pennsylvania & Vivodyne	5
25	**Seong Kwon Hur**	허성권	Genentech Inc.	1
26	**Eunju Im**	임은주	Amyloid Solution Inc	6
27	**Myungho Jang**	장명호	GI Innovation	6
28	**Seil Jang**	장세일	UCSF	1
29	**Daeyoung Jeong**	정대영	LegoChem Biosciences	7
30	**Hyang Jo**	조향	Genentech	6
31	**Jeyun Jo**	조제윤	Stanford University/School of Medicine	1
32	**Jiwon Jung**	정지원	Merck & Co.	1
33	**Gyeong Jin Kang**	강경진	Genentech	7
34	**Jaeseung Kang**	강재승	Hanmi Pharm., Co. Ltd.	5
35	**Kicheol Kim**	김기철	Everest Detection	4
36	**Myo-Kyoung Kim**	김묘경	University of the Pacific	4
37	**Jeonghyeon Kim**	김정현	Stanford University	4
38	**Sunmi Kim**	김선미	PharmEng Technology	6
39	**Sehyun Kim**	김세현	Merck	6
40	**Soyon Kim**	김소연	GC Cell	6
41	**Jaeb Kim**	김재범	Gilead Sciences	6
42	**Moon Jeong Kim**	김문정	Matica Biotechnology	3
43	**Sung Ki Kim**	김성기	MGH	3
44	**Ssirai Kim**	김씨래	Eli Lilly and Company	3
45	**Sang Kim**	김상엽	Merck	1
46	**Seokjoong Kim**	김석중	GenEdit	1
47	**Sun Kyung Kim**	김선경	Lawrence Livermore National Laboratory	1
48	**Soojin Kim**	김수진	Genentech	1
49	**Lee Joon Kim**	김이준	LBNL	1
50	**John Kim**	김준연	Omniab	1
51	**Karam Kim**	김가람	Genentech	5
52	**Jungwon Kim**	김정원	Cytogen Health	2
53	**Youngjun Koh**	고영준	GI Innovation	6
54	**Jadon Koo**	구자돈	Cytogen Health	2
55	**Valentina Kwak**	곽승화	Ambagon Therapeutics	1
56	**Boram Lee**	이보람	Merck	4
57	**Hee Jung Lee**	이희정	Penumbra Inc	4
58	**Kunwoo Lee**	이근우	GenEdit	6
59	**Agatha Lee**	이동은	Batavia Biosciences	6
60	**Wonjae Lee**	이원재	Kanaph Therapeutics	6
61	**Jaecheon Lee**	이재천	ABL Bio Inc.	6
62	**Jungha Lee**	이정하	GC Cell	6
63	**Hyuncheol Lee**	이현철	Vivere Oncotherapies	6
64	**Yunkyeong Lee**	이윤경	Stanford University	7
65	**Seokjoo Lee**	이석주	SK Pharmteco	3
66	**Jamie Lee**	이지현	Veterans Affairs	3
67	**Sungjin Lee**	이성진	Surrozen	1
68	**Michelle Lee**	이지원	Stanford University	1
69	**Hyunbin Lee**	이현빈	Stanford university	1
70	**Hye Lim Lee**	이혜림	UCSF	1
71	**Jae Yun Lee**	이재윤	Hanmi Pharm., Co. Ltd.	5
72	**Jae Moon Lee**	이재문	FAScinate Therapeutics	2
73	**Hwajin Lee**	이화진	경희대학교/업테라	2
74	**Hanjo Lim**	임한조	Genentech	7
75	**Won Young Lim**	임원영	Ascendis pharma	3
76	**Sunghoon Ma**	마성훈	Independent Drug Discovery	1
77	**Jung Il Moon**	문정일	Genentech	1

KASBP-SF Symposium 2024 Attendees

Early Bird registrants only

78	**Peter Moon**	문형근	Genentech	1
79	**Sander Myoung**	명성현	Bridgene Biosciences	1
80	**Jaehak Oh**	오재학	Amgen	1
81	**Ik-Hyeon Paik**	백익현	Wave Life Sciences, Inc.	1
82	**Ji Won Park**	박지원	Genentech/Roche	4
83	**Young Bin Park**	박영빈	Calici	1
84	**James Park**	박제임스	GC Cell	1
85	**Hangil Park**	박한길	Walking Fish Therapeutics	1
86	**Hyeri Park**	박혜리	Kimia Therapeutics	1
87	**Young-Seoub Park**	박영섭	세라트젠	5
88	**Hyo Min Park**	박효민	GenEdit	2
89	**Siyeon Rhee**	리시연	Stanford University	1
90	**BG Rhee**	이병건	GI Innovation	2
91	**Jeongin Son**	손정임	Amgen	7
92	**Sunny Song**		WuXi Biologics	6
93	**Yvonne Ehwang Song**	송이황	Thermo Fisher Scientific	7
94	**Christina Song**	송숙영	Amgen	2
95	**Jinsook Suh**	서진숙	Wildtype	7
96	**Yunju Yang**	양윤주	Character Bioscience	1
97	**Ohkyu Yoon**	윤오규	Gilead Sciences	4
98	**Taewon Yoon**	윤태원	Yuhan USA	6
99	**Jung-Ki Yoon**	윤정기	Stanford University	5
100	**Kwontae You**	유권태	Orion Medicines	1
101	**Nari Yun**	윤나리	GI Innovation	2

■ Networking Groups (2024 KASBP-SF Symposium)

	Networking group
1	Discovery - Early Development of Therapeutics
2	Translational & Clinical Research, Biomarker
3	CMC, Manufacturing, & Late Development of Therapeutics / Regulatory Affairs
4	AI / ML, Bioinformatics, Statistics
5	Platforms & Enabling Technologies
6	Business Development, Venture Capital, Corporate Development
7	Career Development

NOTE



Korean American Society in Biotech and Pharmaceuticals
재미한인제약인협회

KASBP
SAN FRANCISCO

Contact Us
KASBP San Francisco
www.kasbpsf.org